Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATEMPT: T-DM1 vs Paclitaxel + Trastuzumab in Stage I HER2+ Breast Cancer
NCT01853748Phase 2Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- May 2013
- Primary completion
- Aug 2019
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of trastuzumab emtansine in breast cancer, sponsored by Dana-Farber Cancer Institute. Started May 2013; status: completed.
02
Drugs
trastuzumab emtansine
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT01853748.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01853748.